Post-translational Modification of KRAS: Potential Targets for Cancer Therapy

Overview

Journal Acta Pharmacol Sin

Specialty Pharmacology

Date 2020 Oct 22

PMID 33087838

Citations 22

Authors

Wei-Hua Wang

Tao Yuan

Mei-Jia Qian

Fang-Jie Yan

Liu Yang

Qiao-Jun He

Bo Yang

Jin-Jian Lu

Hong Zhu

Affiliations

Soon will be listed here.

Abstract

Aberrant activation of the RAS superfamily is one of the critical factors in carcinogenesis. Among them, KRAS is the most frequently mutated one which has inspired extensive studies for developing approaches to intervention. Although the cognition toward KRAS remains far from complete, mounting evidence suggests that a variety of post-translational modifications regulate its activation and localization. In this review, we summarize the regulatory mode of post-translational modifications on KRAS including prenylation, post-prenylation, palmitoylation, ubiquitination, phosphorylation, SUMOylation, acetylation, nitrosylation, etc. We also highlight the recent studies targeting these modifications having exhibited potent anti-tumor activities.

Citing Articles

Anti-proteolytic regulation of KRAS by USP9X/NDRG3 in KRAS-driven cancer development.

Koo H, Park K, Sohn H, Kang M, Kim D, Park Z Nat Commun. 2025; 16(1):628.

PMID: 39819877 PMC: 11739382. DOI: 10.1038/s41467-024-54476-8.

Insights into direct KRAS inhibition strategies for cancer treatment.

Li T, Gu C, Zhou C, Mao C, Yang K, Xu J Future Med Chem. 2024; 16(22):2411-2429.

PMID: 39569642 PMC: 11622815. DOI: 10.1080/17568919.2024.2424149.

PPM1G Inhibits Epithelial-Mesenchymal Transition in Cholangiocarcinoma by Catalyzing TET1 Dephosphorylation for Destabilization to Impair Its Targeted Demethylation of the CLDN3 Promoter.

Liu W, Kuai Y, Wang D, Chen J, Xiong F, Wu G Adv Sci (Weinh). 2024; 11(47):e2407323.

PMID: 39477806 PMC: 11653675. DOI: 10.1002/advs.202407323.

Altered glycosylation in cancer: molecular functions and therapeutic potential.

Xu X, Peng Q, Jiang X, Tan S, Yang W, Han Y Cancer Commun (Lond). 2024; 44(11):1316-1336.

PMID: 39305520 PMC: 11570773. DOI: 10.1002/cac2.12610.

OTU deubiquitinase, ubiquitin aldehyde binding 2 (OTUB2) modulates the stemness feature, chemoresistance, and epithelial-mesenchymal transition of colon cancer via regulating GINS complex subunit 1 (GINS1) expression.

Zhu W, Wu C, Liu Z, Zhao S, Huang J Cell Commun Signal. 2024; 22(1):420.

PMID: 39210373 PMC: 11361113. DOI: 10.1186/s12964-024-01789-2.

References

Sung P, Tsai F, Vais H, Court H, Yang J, Fehrenbacher N . Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors. Proc Natl Acad Sci U S A. 2013; 110(51):20593-8. PMC: 3870738. DOI: 10.1073/pnas.1306431110. View

Lander H, Ogiste J, Pearce S, Levi R, Novogrodsky A . Nitric oxide-stimulated guanine nucleotide exchange on p21ras. J Biol Chem. 1995; 270(13):7017-20. DOI: 10.1074/jbc.270.13.7017. View

Zhang F, Casey P . Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996; 65:241-69. DOI: 10.1146/annurev.bi.65.070196.001325. View

Siprashvili Z, Webster D, Johnston D, Shenoy R, Ungewickell A, Bhaduri A . The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer. Nat Genet. 2015; 48(1):53-8. PMC: 5324971. DOI: 10.1038/ng.3452. View

Bergo M, Ambroziak P, Gregory C, George A, Otto J, Kim E . Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol. 2001; 22(1):171-81. PMC: 134215. DOI: 10.1128/MCB.22.1.171-181.2002. View

Marin-Ramos N, Balabasquer M, Ortega-Nogales F, Torrecillas I, Gil-Ordonez A, Marcos-Ramiro B . A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia. J Med Chem. 2019; 62(13):6035-6046. DOI: 10.1021/acs.jmedchem.9b00145. View

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

Laude A, Prior I . Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain. J Cell Sci. 2008; 121(Pt 4):421-7. DOI: 10.1242/jcs.020107. View

Vetter I, Wittinghofer A . The guanine nucleotide-binding switch in three dimensions. Science. 2001; 294(5545):1299-304. DOI: 10.1126/science.1062023. View

10.

Amendola C, Mahaffey J, Parker S, Ahearn I, Chen W, Zhou M . KRAS4A directly regulates hexokinase 1. Nature. 2019; 576(7787):482-486. PMC: 6923592. DOI: 10.1038/s41586-019-1832-9. View

11.

Zeng T, Wang Q, Fu J, Lin Q, Bi J, Ding W . Impeded Nedd4-1-mediated Ras degradation underlies Ras-driven tumorigenesis. Cell Rep. 2014; 7(3):871-82. DOI: 10.1016/j.celrep.2014.03.045. View

12.

Bigenzahn J, Collu G, Kartnig F, Pieraks M, Vladimer G, Heinz L . LZTR1 is a regulator of RAS ubiquitination and signaling. Science. 2018; 362(6419):1171-1177. PMC: 6794158. DOI: 10.1126/science.aap8210. View

13.

Dharmaiah S, Tran T, Messing S, Agamasu C, Gillette W, Yan W . Structures of N-terminally processed KRAS provide insight into the role of N-acetylation. Sci Rep. 2019; 9(1):10512. PMC: 6642148. DOI: 10.1038/s41598-019-46846-w. View

14.

Alcock R, Dey S, Chendil D, Inayat M, Mohiuddin M, Hartman G . Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Oncogene. 2002; 21(51):7883-90. DOI: 10.1038/sj.onc.1205948. View

15.

Hu C, Tien S, Hsieh P, Jeng Y, Chang M, Chang Y . High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells. Cell Metab. 2019; 29(6):1334-1349.e10. DOI: 10.1016/j.cmet.2019.02.005. View

16.

Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M . Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. Clin Cancer Res. 2019; 25(19):5984-5996. PMC: 6774803. DOI: 10.1158/1078-0432.CCR-18-3399. View

17.

Choi B, Philips M, Chen Y, Lu L, Dai W . K-Ras Lys-42 is crucial for its signaling, cell migration, and invasion. J Biol Chem. 2018; 293(45):17574-17581. PMC: 6231119. DOI: 10.1074/jbc.RA118.003723. View

18.

Lobell R, Liu D, Buser C, Davide J, DePuy E, Hamilton K . Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther. 2002; 1(9):747-58. View

19.

Cho K, Casteel D, Prakash P, Tan L, van der Hoeven D, Salim A . AMPK and Endothelial Nitric Oxide Synthase Signaling Regulates K-Ras Plasma Membrane Interactions via Cyclic GMP-Dependent Protein Kinase 2. Mol Cell Biol. 2016; 36(24):3086-3099. PMC: 5126295. DOI: 10.1128/MCB.00365-16. View

20.

Lander H, Ogiste J, Teng K, Novogrodsky A . p21ras as a common signaling target of reactive free radicals and cellular redox stress. J Biol Chem. 1995; 270(36):21195-8. DOI: 10.1074/jbc.270.36.21195. View